SCHEMBL25682137

SCHEMBL25682137

c1ccc(-c2cccc(-c3nc(-c4ccccc4)nc(-c4cc5c(oc6cccc(-c7ccc8ccccc8c7)c65)c5ccccc45)n3)c2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.37
KDM4E B2RXH2 2/20 0.37
TP53 P04637 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
HSD17B10 Q99714 2/20 0.37
MEN1 O00255 1/20 0.37
CYP1A2 P05177 1/20 0.37
KMT2A Q03164 1/20 0.37
ALOX5 P09917 1/20 0.37
MAPT P10636 3/20 0.34
PRKDC P78527 1/20 0.34
HPGD P15428 2/20 0.34
TSHR P16473 1/20 0.34
NFKB1 P19838 1/20 0.34
MAPK1 P28482 1/20 0.34
NFKB2 Q00653 1/20 0.34
RELA Q04206 1/20 0.34
ATM Q13315 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25681970 0.99 ALOX5 (0.38) ALDH1A1KDM4ETP53SMN1; SMN2HSD17B10
SCHEMBL25676130 0.98 ALDH1A1 (0.39) ALDH1A1KDM4ETP53SMN1; SMN2HSD17B10
SCHEMBL26243955 0.97 ALDH1A1 (0.38) ALDH1A1KDM4ETP53SMN1; SMN2HSD17B10
SCHEMBL24586060 0.97 ALDH1A1 (0.39) ALDH1A1KDM4ETP53SMN1; SMN2HSD17B10
SCHEMBL25681968 0.97 ALDH1A1 (0.39) ALDH1A1KDM4ETP53SMN1; SMN2HSD17B10
SCHEMBL26243910 0.97 ALDH1A1 (0.39) ALDH1A1KDM4ETP53SMN1; SMN2HSD17B10
SCHEMBL23034173 0.96 ALDH1A1 (0.37) ALDH1A1KDM4ETP53SMN1; SMN2HSD17B10
SCHEMBL24521269 0.96 ALDH1A1 (0.37) ALDH1A1KDM4ETP53SMN1; SMN2HSD17B10
SCHEMBL25679332 0.96 ALDH1A1 (0.39) ALDH1A1KDM4ETP53SMN1; SMN2HSD17B10
SCHEMBL25679422 0.96 ALDH1A1 (0.39) ALDH1A1KDM4ETP53SMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230292601-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT MATERIALS CO., LTD. (KR) 2023-09-14 US disclosed
US-20230292601-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT MATERIALS CO., LTD. (KR) 2023-09-14 US disclosed
EP-4201931-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT Materials Co., Ltd. (KR) 2023-06-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230292601-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME ORC3, CRY1, SUN2 ALDH1A1 458/4885KDM4E 2700/4885TP53 2361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.